Robert D. Toto

Active 1990–2025

Also published as
Robert D Toto
124
Papers
28,596
Citations
79
h-index
122
i10-index

Citations

Citations per year for Robert D. Toto1992: 1 citations1993: 4 citations1994: 1 citations1995: 5 citations1996: 6 citations1997: 14 citations1998: 21 citations1999: 18 citations2000: 15 citations2001: 23 citations2002: 56 citations2003: 74 citations2004: 115 citations2005: 117 citations2006: 122 citations2007: 131 citations2008: 97 citations2009: 140 citations2010: 154 citations2011: 177 citations2012: 206 citations2013: 234 citations2014: 228 citations2015: 199 citations2016: 153 citations2017: 180 citations2018: 160 citations2019: 667 citations2020: 710 citations2021: 729 citations2022: 733 citations2023: 675 citations2024: 1,041 citations2025: 556 citations2026: 24 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,855 citing papers, 24.3% of this breakdownUnited Kingdom: 835 citing papers, 7.1% of this breakdownChina: 796 citing papers, 6.8% of this breakdownGermany: 660 citing papers, 5.6% of this breakdownItaly: 577 citing papers, 4.9% of this breakdownAustralia: 528 citing papers, 4.5% of this breakdownJapan: 514 citing papers, 4.4% of this breakdownCanada: 487 citing papers, 4.2% of this breakdownNetherlands: 467 citing papers, 4% of this breakdownSpain: 333 citing papers, 2.9% of this breakdownFrance: 309 citing papers, 2.6% of this breakdownSweden: 237 citing papers, 2% of this breakdown
0%24.3%Other 26.7%

Fields

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology11.8%
  • Health Professions1.2%
  • Nursing1.1%
  • Immunology and Microbiology0.8%
  • Neuroscience0.8%
  • Other2.8%

Topics

  • Chronic Kidney Disease and Diabetes8.6%
  • Dialysis and Renal Disease Management7.5%
  • Diabetes Treatment and Management6.8%
  • Blood Pressure and Hypertension Studies5.6%
  • Erythropoietin and Anemia Treatment2.5%
  • Hormonal Regulation and Hypertension2.4%
  • Other66.6%

Coauthors

All papers

Open in search
  1. An atlas of healthy and injured cell states and niches in the human kidney

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sylvia E. Rosas, F. Perry Wilson, Paul M. Palevsky, Krzysztof Kiryluk, John R. Sedor, Robert D. Toto, Chirag R. Parikh, Eric H. Kim, Rahul Satija, Anna Greka, Evan Z. Macosko, Peter V. Kharchenko, Joseph P. Gaut, Jeffrey B. Hodgin, Richard A. Knight, Stewart H. Lecker, Isaac E. Stillman, Afolarin Amodu, Titlayo Ilori, Shana Maikhor, Insa M. Schmidt, Gearoid M. McMahon, Astrid Weins, Nir Hacohen, Lakeshia Bush, Agustin Gonzalez‐Vicente, Jonathan J. Taliercio, John O’Toole, Emilio D. Poggio, Leslie Cooperman, Stacey E. Jolly, Leal Herlitz, Jane Nguyen, Ellen L. Palmer, Dianna Sendrey, Kassandra Spates-Harden, Paul S. Appelbaum, Jonathan Barasch, Andrew S. Bomback, Vivette D. D’Agati, Karla Mehl, Pietro A. Canetta, Ning Shang, Olivia Balderes, Satoru Kudose, Laura Barisoni, Theodore Alexandrov, Ying‐Hua Cheng, Kenneth W. Dunn, Katherine J. Kelly, Timothy A. Sutton, Yumeng Wen, Celia P. Corona-Villalobos, Steven Menez, Avi Z. Rosenberg, Mohammed Atta, Camille Johansen, Jennifer K. Sun, Neil Roy, Mark Williams, Evren U. Azeloglu, Cijang He, Ravi Iyengar, Jens Hansen, Yuguang Xiong, Brad H. Rovin, Samir V. Parikh, Sethu M. Madhavan, Christopher Anderton, Ljiljana Paša‐Tolić and 70 more - Nature 2023 cited by 693

  2. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    Authors: , , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2020 cited by 530

  3. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 994

  4. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA 2018 cited by 1,087

  5. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

    Authors: , , , , , , , , , , , , , , - Kidney International 2021 cited by 397

  6. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eduardo Verde, Eduardo Gutiérrez, Enyu Imai, Fan Fan Hou, Fernando Caravaca, Fernando C. Fervenza, Francesco Locatelli, Francesco Paolo Schena, Fumiaki Kobayashi, Gabriella Moroni, Gavin J. Becker, Gerald J. Beck, Gerald B. Appel, Gershon Frisch, GG van Essen, Giuseppe Maschio, Giuseppe Remuzzi, Giuseppe Montogrino, Hans‐Henrik Parving, Hiddo J.L. Heerspink, Hirofumi Makino, Imitiaz Jehan, Jack F.M. Wetzels, James V. Donadío, Jamie P. Dwyer, Jan A.J.G. van den Brand, John W. Kusek, John M. Lachin, José Luño, Julia B. Lewis, Jürgen Floege, Kaleab Z. Abebe, K.-M. Chow, Lawrence G. Hunsicker, Lucia Del Vecchio, Manno Carlo, Manuel Praga, Marián Goicoechea, Maximilian von Eynatten, Neil Poulter, Nish Chaturvedi, Patrizia Passerini, Paul E. de Jong, Peter J. Blankestijn, Philip H. Li, Piero Ruggenenti, P Zucchelli, Priscilla Kincaid‐Smith, R.-D Hilgers, Raymond O. Estacio, Richard D. Rohde, Ritsuko Katafuchi, Robert D. Toto, Robert W. Schrier, Roger A. Rodby, Ronald D. Perrone, Sadayoshi Ito, Saulo Klahr, Simeone Andrulli, Svend Strandgaard, Tak Mao Chan, Thierry Hannedouche, Thomas Rauen, Tom Greene, Úrsula Verdalles, Vlado Perkovic, William F. Keane - The Lancet Diabetes & Endocrinology 2019 cited by 372

  7. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brendan J. Barrett, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, David W. Johnson, Meg Jardine, Maximilian von Eynatten, Eduardo Verde, Úrsula Verdalles, David Arroyo, Arlene B. Chapman, Vicente E. Torres, Alan S.L. Yu, Godela Brosnahan, Thierry Hannedouche, Kai‐Ming Chow, Cheuk‐Chun Szeto, Chi‐Bon Leung, Di Xie, Fan Fan Hou, Jamie P. Dwyer, Marc A. Pohl, Itamar Raz, Lawrence G. Hunsicker, An Vanacker, Thomas Malfait, Giuseppe Maschio, Francesco Locatelli, Peter J. Blankestijn, Arjan van Zuilen, Fumiaki Kobayashi, Hirofumi Makino, Juliana C.N. Chan, Simeone Andrulli, Claudio Pozzi, Donatella Casartelli, Manuel Praga, Hernando Trujillo, Teresa Cavero, Ángel Sevillano, Piero Ruggenenti, Annalisa Perna, Fabiola Carrara, William F. Keane, Carlo Manno, Richard Haynes, William G. Herrington, Colin Baigent, Martin Landray, Thomas Rauen, Claudia Seikrit, Stefanie Wied, Robert D. Toto, Paul E. de Jong, Mauro Saddelli - Nature Medicine 2023 cited by 157

  8. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 876

  9. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Authors: , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2021 cited by 208

  10. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 2,076

  11. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    Authors: , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2021 cited by 196

  12. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    Authors: , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2021 cited by 194

  13. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roland E. Schmieder, Christoph Wanner, Pantelis Sarafidis, Juliana C.N. Chan, László Rosivall, Joseph A. Eustace, Ehud Grossman, Yoram Yagil, Giuseppe Remuzzi, Daisuke Koya, Takashi Wada, Magdalena Madero Rovalo, Ron T. Gansevoort, Adriaan Kooy, Trine Finnes, Froilan DeLeon, Janusz Gumprecht, Fernando Teixeira e Costa, Alexander Dreval, Anantharaman Vathsala, Aslam Amod, Sin Gon Kim, Byung‐Wan Lee, Julio Pascual Santos, Bengt-Olov Tengmark, Michel Burnier, Chien‐Te Lee, Sukit Yamwong, Ramazan Sarı, Kieran McCafferty, Borys Mankovsky, Sharon G. Adler, Linda F. Fried, Mark V. Williams, Tran Quang Khanh, Diego Aizenberg, Inés Bartolacci, Diego Besada, Julio Bittar, Mariano Chahin, Alicia Elbert, Elizabeth Gelersztein, Alberto Liberman, Laura Maffei, Federico Pérez Manghi, Hugo Sanabria, Gloria Viñes, Alfredo Wassermann, Walter P. Abhayaratna, Shamasunder Acharya, Elif I. Ekinci, Darren Lee, Peak Mann Mah, Craig Nelson, David Packham, Alexia Pape, Simon Roger, Hugo Stephenson, Michael Suranyi, Gary Wittert, Elizabeth Vale, Martin Clodi, Christoph Ebenbichler, Evelyn Fließer-Görzer, Ursula Hanusch, Michael Krebs, Karl Lhotta, Bernhard Ludvik, Gert Mayer, Peter Neudorfer and 1,447 more - Annals of Internal Medicine 2023 cited by 88

  14. Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases

    Authors: , , - Hypertension 2014 cited by 251

  15. Rationale and design of the Kidney Precision Medicine Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chirag R. Parikh, Emilio D. Poggio, Sylvia E. Rosas, Matthew R. Rosengart, Minnie Sarwal, Jennifer A. Schaub, John R. Sedor, Kumar Sharma, Becky Steck, Robert D. Toto, Olga G. Troyanskaya, Katherine R. Tuttle, Miguel A. Vazquez, Sushrut S. Waikar, Kayleen Williams, F. Perry Wilson, Kun Zhang, Ravi Iyengar, Matthias Kretzler, Jonathan Himmelfarb, Richard Knight, Stewart H. Lecker, Isaac E. Stillman, Sushrut S. Waikar, Gearoid M. McMahon, Astrid Weins, Samuel Short, Nir Hacohen, Paul Hoover, Mark P. Aulisio, Leslie Cooperman, Leal Herlitz, John O’Toole, Emilio D. Poggio, John R. Sedor, Stacey E. Jolly, Paul S. Appelbaum, Olivia Balderes, Jonathan Barasch, Andrew S. Bomback, Pietro A. Canetta, Vivette D. D’Agati, Krzysztof Kiryluk, Satoru Kudose, Karla Mehl, Jai Radhakrishnan, Chenhua Weng, Laura Barisoni, Theodore Alexandrov, Tarek Ashkar, Daria Barwinska, Pierre C. Dagher, Kenneth W. Dunn, Michael T. Eadon, Michael J. Ferkowicz, Katherine J. Kelly, Timothy A. Sutton, Seth Winfree, Steven Menez, Chirag R. Parikh, Avi Z. Rosenberg, Pam Villalobos, Rubab F. Malik, Derek M. Fine, Mohammed Atta, Jose Manuel Monroy Trujillo, Alison Slack, Sylvia E. Rosas, Mark Williams, Evren U. Azeloglu and 98 more - Kidney International 2021 cited by 190

  16. An atlas of healthy and injured cell states and niches in the human kidney

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John R. Sedor, Robert D. Toto, Chirag R. Parikh, Eric H. Kim, Evan Z. Macosko, Peter V. Kharchenko, Joseph P. Gaut, Jeffrey B. Hodgin, Michael T. Eadon, Pierre C. Dagher, Tarek M. El‐Achkar, Kun Zhang, Matthias Kretzler, Sanjay Jain - 2021 cited by 117

  17. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink - Nephrology Dialysis Transplantation 2020 cited by 190

  18. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

    Authors: , , , , , , , , , , , , - Journal of the American Society of Nephrology 2022 cited by 86

  19. Prediction of Mortality and Major Adverse Kidney Events in Critically Ill Patients With Acute Kidney Injury

    Authors: , , , , , , , , , - American Journal of Kidney Diseases 2022 cited by 73

  20. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

    Authors: , , , , , , , , , , , , , , - NEJM Evidence 2023 cited by 67

  21. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    Authors: , , , , , , , , , , , , , , - 2021 cited by 101

  22. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2021 cited by 73

  23. Resistant Hypertension: Diagnosis, Evaluation, and Treatment

    Authors: , , , , , , , , , , , , , - Circulation 2008 cited by 2,238

  24. Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2002 cited by 1,875